Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9794—Liliopsida [monocotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/04—Preparations for care of the skin for chemically tanning the skin

Definitions

• the present invention relates to compositions containing a peptide(s) and a pigment (s) and the use thereof in darkening the skin.
• the darkening of skin color is a concern for many individuals. Most people obtain darker skin through exposure to UV light (e.g., suntanning or UV lamps) . UV exposure, however, results in accelerated skin aging and increased incidence of skin cancer. The ability to generate a tanned appearance without incurring photodamage, thus, is important to many individuals. Accordingly, alternative methods for "sunless tanning” have evolved. One method is the use of products containing dihydroxy acetone (DHA) . Some of these products, however, produce color that is too orange and unnatural to the user. Moreover, the DHA-produced skin color only minimally protects the user from UV irradiation. Products containing beta-carotene and cantaxanthin have also been used to darken the skin.
• DHA dihydroxy acetone
• the present invention relates to compositions containing a peptide(s) and a pigment (s) and the use thereof in darkening the skin.
• tanning the skin is darkening the appearance of the skin, including, but not limited to, tanning the skin.
• topical applying means directly laying on or spreading on outer skin using, e.g., by use of the hands or an applicator such as a wipe, roller, or spray.
• cosmetically-acceptable means that the peptides, pigments, or inert ingredients which the term describes are suitable for use in contact with tissues
• safe and effective amount means an amount of the peptide or composition sufficient to induce a darkening of the skin, but low enough to avoid serious side effects.
• the safe and effective amount of the compound or composition will vary with the area being treated, the age and skin type of the end user, the duration and nature of the treatment, the specific compound or composition employed, the particular cosmetically-acceptable carrier utilized, and like factors .
• Pigment What is meant by a “pigment” is a compound (s) that can be taken up by epidermal cells in the presence of the peptides described below, resulting in visually darker look to the skin.
• pigments include, but not limiting to, melanin and melanin derivatives (e.g, both melanin polymers and lower molecular weight water-soluble melanin derivatives) ; extracts from natural sources containing pigments (e.g., brown pigments from plants from the Hedychium genus or Bearberry genus or yellow, orange and red pigments, from plants containing carotenoids or canthaxanthins) ; or synthetic chemicals such as compounds containing copper (e.g., copper salts such as CuCl 2 ) or synthetic carotenoids or canthaxantins .
• melanin and melanin derivatives e.g, both melanin polymers and lower molecular weight water-soluble melanin derivatives
• extracts from natural sources containing pigments e
• an “extract” is a mixture of compounds isolated from a natural source (e.g., a plant).
• Examples of synthetic melanin derivatives are disclosed in U.S. Patent Nos. 5,618,519, 5,384,116, and 5,227,459.
• Examples of soluble melanin derivatives are disclosed in 5,744,125, 5,225,435, 5,218,079, and 5,216,116.
• Examples of commercially available soluble melanin derivatives include Melasyn-100TM from San-mar laboratories, Inc. (Elmsford, NY) and MelanZeTM from Zylepsis (Ashford, Kent, United Kingdom) .
• the amount of pigment present in the composition will depend on the type of pigment used.
• the pigment typically will be present in the composition in an amount from about 0.001% to about 20% by weight, in particular in an amount from about 0.005% to about 5% by weight.
• composition of the present invention comprises a peptide of the formula I
• Ai is Ser or 2,3-diaP, or is absent
• a 2 is Val, Leu, He, or Cha;
• a 3 is Val, Leu, He, or Cha;
• a 4 is Gly or Ala;
• a 5 is Lys, Arg, or Har;
• a 6 is Val, Leu, He, or Cha, or is absent;
• R 3 is OH, NH 2 , C ⁇ - 12 alkoxy, C 7 _ ⁇ 0 phenylalkoxy, Cn-20 naphthylalkoxy, C ⁇ - 12 alkylamino, C 7 _ ⁇ 0 phenylalkylamino, or C 11-20 naphthylalkylamino; or a cosmetically acceptable salt thereof.
• R x and R 2 which are bound to the N- terminus of the peptide, are both H.
• peptides of the present invention include, but are not limited to, H 2 -Leu-Ile-Gly-Arg-NH 2 (Peptide 1; SEQ. ID.No.1) , H 2 -Leu-Ile-Gly-Arg-OH (Peptide 2; SEQ. ID. No.2) , H 2 -Ser-Leu-Ile-Gly-Arg-Leu-NH 2 (Peptide 3; SEQ. ID.No.3) , and H 2 -Ser-Leu-Ile-Gly-Arg-Leu-0H (Peptide 4;
• Arg-NH 2 (Peptide 9; SEQ. ID.No.9) , Stearatoyl-Leu-Ile-Gly- Arg-OH (Peptide 10; SEQ . ID.No.10) , Stearatoyl-Ser-Leu-Ile- Gly-Arg-Leu-NH 2 (Peptide 11; SEQ.ID.No.il) , and Stearatoyl- Ser-Leu-Ile-Gly-Arg-Leu-OH (Peptide 12; SEQ. ID.No.12) , or a cosmetically-acceptable salt thereof.
• the symbol A x , A 2 , or the like used herein stands for the residue of an alpha-amino acid.
• R 2 are both bound to the free nitrogen atom N-terminal amino acid (e.g., A % or A 2 ) and the R 3 is bound to the free carboxy group of the C-terminal amino acid (e.g., A 5 , As, or A 7 ) .
• Cha herein refers to cyclohexyla.lan.me
• 2,3-diaP refers to 2, 3-diaminoproprionic acid
• Hard refers to homoarginine.
• amino acid residue is optically active, it is the L-form configur tion that is intended unless the D-form is expressly designated.
• An alkyl group if not specified, contains 1-12 carbon atoms.
• the peptide of the invention can be provided in the form of cosmetically acceptable salts.
• Examples of preferred salts are those with therapeutically acceptable organic acids, e.g., acetic, palmitic, oleic, stearic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, salicylic, methanesulfonic, or pamoic acid, as well as polymeric acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids such as the hydrohalic acids (e.g., hydrochloric acid), sulfuric acid or phosphoric acid.
• the amount of peptide present in the composition will depend on the peptide used.
• the peptide typically will be present in the composition in an amount from about 0.001% to about 10% by weight, in particular in an amount from about 0.005% to about 5% by weight.
• compositions useful in the present invention involve formulations suitable for topical application to skin.
• the composition comprises the peptide, pigment, and a cosmetically- acceptable topical carrier.
• the cosmetically-acceptable topical carrier is from about 50% to abut 99.99%, by weight, of the composition (e.g., from about 80% to about 95%, by weight, of the composition.
• compositions may be made into a wide variety of product types that include but are not limited to lotions, creams, gels, sticks, sprays, ointments, cleansing liquid washes and solid bars, shampoos, pastes, foams, powders, mousses, shaving creams, wipes, patches, nail lacquers, wound dressing and adhesive bandages, hydrogels, films and make-up such as foundations, mascaras, and lipsticks.
• product types may comprise several types of cosmetically- acceptable topical carriers including, but not limited to solutions, emulsions (e.g., microemulsions and nanoemulsions) , gels, solids and liposo es. The following are non-limitative examples of such carriers.
• Topical compositions useful in the present invention can be formulated as solutions. Solutions typically include an aqueous or organic solvent (e.g., from about 50% to about 99.99% or from about 90% to about 99% of a cosmetically acceptable aqueous or organic solvent). Examples of suitable organic solvents include: propylene glycol, polyethylene glycol (200-600) , polypropylene glycol (425-2025), glycerol, 1,2,4- butanetriol, sorbitol esters, 1, 2, 6-hexanetriol, ethanol, and mixtures thereof . Topical compositions useful in the subject invention may be formulated as a solution comprising an emollient.
• compositions preferably contain from about 2% to about 50% of an emollien (s) .
• emollients refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin.
• suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972) and the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen, pp. 1656-61, 1626, and 1654-55 (The Cosmetic, Toiletry, and Fragrance Assoc, Washington, D.C., 7 th Edition, 1997) (hereinafter "ICI Handbook”) contains numerous examples of suitable materials.
• a lotion can be made from such a solution.
• Lotions typically comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient (s) and from about 50% to about 90% (e.g., from about 60% to about 80%) of water.
• a cream typically comprises from about 5% to about 50% (e.g., from about 10% to about 20%) of an emollient (s) and from about 45% to about 85% (e.g., from about 50% to about 75%) of water.
• An ointment may comprise a simple base of animal or vegetable oils or semi-solid hydrocarbons.
• An ointment may comprise from about 2% to about 10% of an emollient (s) plus from about 0.1% to about
• compositions useful in the present invention formulated as emulsions.
• the carrier is an emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the carrier comprises an emulsifier (s) .
• Emulsifiers may be nonionic, anionic or cationic.
• Suitable emulsifiers are disclosed in, for example, U.S.
• Patent No. 3,755,560 U.S. Patent No. 4,421,769, McCutcheon's Detergents and Emulsifiers, North American
• Lotions and creams can be formulated as emulsions.
• Such lotions comprise from 0.5% to about 5% of an emulsifier (s) .
• Such creams would typically comprise from about 1% to about 20% (e.g., from about 5% to about (e.g., from 30% to about 70%) of water; and from about 1% to about 10% (e.g., from about 2% to about 5%) of an emulsifier (s) .
• Single emulsion skin care preparations such as lotions and creams, of the oil-in-water type and water-in- oil type are well-known in the cosmetic art and are useful in the subject invention.
• Multiphase emulsion compositions such as the water-in-oil-in-water type, as disclosed in U.S. Patent No. 4,254,105 and 4,960,764, are also useful in the subject invention.
• such single or multiphase emulsions contain water, emollients, and emulsifiers as essential ingredients.
• the topical compositions of this invention can also be formulated as a gel (e.g., an aqueous, alcohol, alcohol/water, or oil gel using a suitable gelling agent (s) ) .
• suitable gelling agents for aqueousand/or alcoholic gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose) .
• Suitable gelling agents for oils include, but are not limited to, hydrogenated butylene/ethylene/styrene copolymer and hydrogenated ethylene/propylene/styrene copolymer.
• Such gels typically comprises between about 0.1% and 5%, by weight, of such gelling agents.
• compositions of the present invention can also be formulated into a solid formulation (e.g., a wax- based stick, soap bar composition, powder, or a wipe containing powder) .
• a solid formulation e.g., a wax- based stick, soap bar composition, powder, or a wipe containing powder
• Liposomal formulations are also useful compositions of the subject invention.
• the peptide and/or the pigment are contained within the liposome. Examples of liposomes are unilamellar, multilamellar, and paucilamellar liposomes, which may or may not contain phospholipids .
• compositions can be prepared by first combining hesperetin with a phospholipid, such as dipalmitoylphosphatidyl choline, cholesterol and water according to the method described in Mezei & Gulasekharam, "Liposomes- -A Selective Drug Delivery System for the
• the liposome is non-ionic.
• the liposome contains (a) glycerol dilaurate; (b) compounds having the steroid backbone found in cholesterol; and (c) fatty acid ethers having from about 12 to about 18 carbon atoms.
• the liposome comprises glycerol dilaurate, cholesterol, polyoxyethylene-10-stearyl ether, and polyoxyethylene-9- lauryl ether. In one embodiment, these ingredients are in a ratio of about 38:12:33:17.
• the liposomes are present in the topical composition in an amount, based upon the total volume of the composition, of from about 10 mg/ml to about 100 mg/ml such as from about 15 mg/ml to about 50 mg/ml.
• Methods of preparing liposomes are well known in the art, such as those disclosed in
• the topical compositions useful in the subject invention may contain, in addition to the aforementioned components, a wide variety of additional oil-soluble materials and/or water-soluble materials conventionally used in compositions for use on skin, hair, and nails at their art-established levels.
• the topical composition further comprises another cosmetically active agent in addition to the peptides and pigments. What is meant by a
• cosmetically active agent is a compound (e.g., a synthetic compound or a compound isolated from a natural source) that has a cosmetic or therapeutic effect on the skin, hair, or nails, including, but not limiting to, lightening agents, darkening agents such as self-tanning agents, anti-acne agents, shine control agents, antimicrobial agents, anti-inflammatory agents, anti-mycotic agents, anti-parasite agents, external analgesics, sunscreens, photoprotectors, antioxidants, keratolytic agents, detergents/surf ctants, moisturizers, nutrients, vitamins, energy enhancers, anti-perspiration agents, astringents, deodorants, hair removers, firming agents, anti-callous agents, and agents for hair, nail, and/or skin conditioning.
• lightening agents such as self-tanning agents, anti-acne agents, shine control agents, antimicrobial agents, anti-inflammatory agents, anti-mycotic agents, anti-parasite agents, external analges
• the agent is selected from, but not limited to, the group consisting of hydroxy acids, benzoyl peroxide, sulfur resorcinol, ascorbic acid, D- panthenol, hydroquinone, octyl methoxycinnimate, titanium dioxide, octyl salicylate, homosalate, avobenzone, polyphenolics, carotenoids, free radical scavengers, spin traps, retinoids such as retinol and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogens, steroids such as hydrocortisone, 2- dimethylaminoethanol, copper salts such as copper chloride, peptides containing copper such as Cu:Gly-His-
• the cosmetically active agent will typically be present in the composition of the invention in an amount of from about 0.001% to about 20% by weight of the composition, e.g., about 0.01% to about 10% such as about 0.1% to about 5%.
• vitamins include, but are not limited to, vitamin A, vitamin Bs such as vitamin B3 , vitamin B5 , and vitamin B12, vitamin C, vitamin K, and vitamin E and derivatives thereof.
• hydroxy acids include, but are not limited, to glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid. See, e.g., European Patent Application No. 273,202.
• antioxidants include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine) , lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide) .
• water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine)
• lipoic acid and dihydrolipoic acid resveratrol, lactoferrin
• ascorbic acid and ascorbic acid derivatives e.g., ascorbyl palmitate and ascorbyl polypeptide
• Oil-soluble antioxidants suitable for use in the compositions of this invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, and ubiqui one .
• Natural extracts containing antioxidants suitable for use in the compositions of this invention include, but not limited to, extracts containing flavonoids and isoflavonoids and their derivatives (e.g., genistein and diadzein) , extracts containing resveratrol and the like. Examples of such natural extracts include grape seed, green tea, pine bark, and propolis. Other examples of antioxidants may be found on pages 1612-13 of the ICI Handbook.
• compositions useful in the subject invention include humectants, proteins and polypeptides, preservatives and an alkaline agent. Examples of such agents are disclosed in the ICI Handbook, pp.1650-1667.
• the compositions of the present invention may also comprise chelating agents (e.g., EDTA) and preservatives (e.g., parabens) . Examples of suitable preservatives and chelating agents are listed in pp. 1626 and 1654-55 of the ICI Handbook.
• the topical compositions useful herein can contain conventional cosmetic adjuvants, such as dyes, opacifiers (e.g., titanium dioxide), pigments, and fragrances .
• compositions of the present invention may be prepared using a mineral water, for example mineral water that has been naturally mineralized such as Evian ® Mineral Water (Evian, France) .
• the mineral water has a mineralization of at least about 200 mg/L
• the mineral water comprises at least about 10 mg/L of calcium and/or at least about 5 mg/L of magnesium.
• compositions and formulations containing such compositions of the present invention may be prepared using methodology that is well known by an artisan of ordinary skill.
• Example 1 Induced pigmentation in culture
• the peptides Peptide 1 and Peptide 3 and various pigments were tested, alone or in combination, with keratinocyte-melanocyte cultures for their effect on cell pigmentation, using DOPA staining and computerized image analysis.
• the pigments that were tested were the pigmented natural extracts Bearberry extract from Alban Muller International (Vincennes, France) and Hedychium spicatum extract sold as Kapur Kachali from Amsar Private Limited (Indore, India), copper chloride from Sigma (St. Louis, MO) and the water-soluble melanin derivatives Melasyn-100TM from San-mar laboratories, Inc. (Elmsford, NY) and
• Human HaCaT keratinocytes (Boukamp P., et al . , J Cell Biol 106, 3, 761-771 (1988)) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (FBS) , 4.5 mg/ml glucose, 2 mM L-glutamine, 50 U/ml penicillin and 50 ⁇ g /ml streptomycin (Life Technologies, Gaithersburg, MD) . Cells were maintained at ⁇ 80% confluency in 5% C0 2 (v/v) and were used in experimental procedures up to culture passage 15.
• DMEM Dulbecco's Modified Eagle's Medium
• FBS fetal bovine serum
• DOPA is a substrate for tyrosinase, therefore an increase in staining represents increased tyrosinase activity and pigment production.
• DOPA-stained monolayers were used for image analysis. All images were obtained and analyzed with Image Pro Plus 3.0 software (Media Cybernetics, Silver Spring, MD) . Parameters measured were surface area of stained material within melanocyte and keratinocytes and the total surface area of the cells in the culture, and the relative pigmented area was calculated. A value of 100% was assigned to untreated controls, and values of treatment groups were normalized to their relevant controls. In all experiments there was no difference between PBS-treated cells and untreated controls. Data are presented with standard deviation (SigmaPlot ® 5.0, SPSS Science, Chicago, IL) .
• Table 1 shows the results of representative co-culture experiments, normalized for their relative controls, demonstrating that the combinations of peptides and pigments of the present invention enhanced pigmentation.
• This Table demonstrates the specificity of the compositions of this invention in inducing pigmentation (e.g., increasing pigmentation by up to 517%) .
• Forskolin Sigma, St. Louis, MO
• a known inducer of pigmentation served as a positive control and a reference point.
• Forskolin was administered at 1% (W/V) .
• Example 2 Induced pigmentation in vivo
• compositions of the present invention were tested for their ability to induce in vivo pigmentation in skin cells in the following experiment .
• Dark skinned Yucatan microswine (Charles River, Portland, ME) were housed in appropriately sized cages in an environmentally controlled room with a 12-hour light - 12-hour dark photoperiod and supplied with food and water ad libi tum.
• Animal care was based on the "Guide for the Care and Use of Laboratory Animals", NIH Publication No. 85-23.
• Twenty ⁇ l of test peptides were applied topically, twice a day, five days/week, for eight or nine weeks, on the dorsum of the swine.
• Sections from the skin biopsies were stained with Hematoxylin and Eosin (H&E) , or with Fontana-Mason (F&M) , using standard procedures (Sheenan DC, Hrapckak BB, eds . , Theory and Practice of Histo-technology. p. 223, 277, The C. V. Mosby Co., St. Louis (1980)).
• F&M staining identifies silver nitrate reducing molecules. In skin, this non-specific stain identifies primarily melanin. At least three sections per biopsy were processed. Each experiment was repeated at least three times.
• Swine were treated with either: the known skin darkening agent forskolin (Sigma) or with a Coleus forskoli extract (ATZ Naturals, Englewood Cliffs, NJ) which contains forskolin, as a positive control at 1%(W/V); pigments at 1% or 5% (W/V) ; peptides of this invention at 250 ⁇ M or 500 ⁇ M; and combinations of such peptides at 250 ⁇ M or 500 ⁇ M with pigments at 1% (W/V) .
• Pigments tested include pigmented natural extracts (i.e., Bearberry extract and Hedychium spicatum extract) and synthetic compounds (i.e., the soluble melanin compound Melasyn-100TM) .
• the gel delivery system consisted of Sepigel 305 (Polyacrylamide & C13-14 isoparaffin & laureth-7 from SEPPIC, Inc. of Fairfield, NJ) . Sepigel 305 was dissolved in the aqueous formulations at 1-3% (W/V) . These delivery systems were also tested in the absence of any pigments or peptides.
• Histological analysis revealed an increase in pigment deposition in swine treated with compositions of this invention. This increase was greater than the darkening induced by forskolin or Coleus forskoli extract, which are known skin darkening agents. Occasionally, an individual swine did not respond to any composition or even forskolin (the positive control) . Such "non-responder" swine composed less than 25% of the total swine treated.
• F&M-stained histological skin sections were evaluated for the change in pigment deposition within the treated site. Criteria for evaluation were total increase in pigment deposition, and the presence of capped epidermal cells above the basal layer.
• Table 3 represents the average value of all sites of responsive swine treated with each test material . The scale for evaluation is defined in Table 2.
• compositions of peptides and pigments of this invention result in increased pigment production and deposition in vivo .
• Example 3 Darkening of human skin
• mice Human skin from patients undergoing cosmetic surgeries was obtained with written consent within 24 hours. Skin was kept in cooled, moist microenvironment prior to dermatoming to 0.4 mm thickness. T cell and B cell deficient mice (Fox Chase C.B-17-SCID, Taconic, NY), six-week-old, were grafted with an oval piece of skin, approximately 0.8x2.0 cm in size. Skin was grafted onto a full thickness skin defect of the shaved mouse and fixed by 6-0 silk. Grafts were covered with Vaseline impregnated gauze and covered by occlusive dressing. Sutures were removed after one week. One month later the human grafts were treated daily, five days a week, for seven weeks, with 15 ⁇ l of test material.
• the human skin was collected for histological analysis.
• the human skins were treated with (i) Peptide 1 (500 ⁇ M) combined with the soluble melanin Melasyn-100TM (1% w/v) in liposomes (20 mg/ml, in PBS) , (ii) Peptide 1 (500 ⁇ M) combined with Bearberry extract (1% w/v) in liposomes (20 mg/ml, in PBS), (iii) Bearberry extract (1% w/v) in liposomes (20 mg/ml, in PBS), or (iv) liposomes alone without peptide or pigments.
• the human skins treated with the peptide and pigment combinations of this invention were visibly darker than an untreated skin graft from the same donor.
• Sections from the skin biopsies were F&M stained as described in Example 2. At least three sections per biopsy were processed. Histological analysis revealed an increase in pigment deposition in the grafts treated with peptide 1 combined with either melanin or Bearberry extract .
• F&M-stained human skin histological sections were evaluated for the change in pigment deposition within the treated site. Criteria for evaluation were total increase in pigment deposition, and the presence of capped epidermal cells above the basal layer, as indicated in Example 2. The results of a representative experiment are described in Table 4.
• compositions of this invention could visibly darken human skin, supported by histological data.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Botany (AREA)
• Biotechnology (AREA)
• Engineering & Computer Science (AREA)
• Dermatology (AREA)
• Cosmetics (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=29581748

Family Applications (1)

Country Status (3)

Family Cites Families (2)

• 2002
  • 2002-05-24 EP EP02734558A patent/EP1507509A1/de not_active Withdrawn
  • 2002-05-24 AU AU2002305718A patent/AU2002305718A1/en not_active Abandoned
  • 2002-05-24 WO PCT/US2002/016713 patent/WO2003099255A1/en not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events